Eight-year outcomes of a phase III randomized trial of conventional versus hypofractionated high-dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): Update from the CHHiP Trial
Birtle, A. J.
Rimmer, Y. L.
Scrase, C. D.
AffiliationInstitute of Cancer Research and The Royal Marsden NHS Foundation Trust, London